Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLCByoung Chul Cho, Patricia Lorenzini, Soon-Hin How et al.|New England Journal of Medicine|2024Cited by 369
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusGiuseppe Curigliano, Uwe G. Liebert, Susana Banerjee et al.|Annals of Oncology|2020Cited by 313
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and ThymomasNicolas Girard, William Pao|Clinical Cancer Research|2009Cited by 193
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung‐Ju Ahn, Jaafar Bennouna, Kentaro Tanaka et al.|Journal of Clinical Oncology|2024Cited by 177
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD. Ross Camidge, Shun Lü, Jair Bar et al.|Journal of Clinical Oncology|2024Cited by 131